Skip to main content
Erschienen in: Clinical and Translational Oncology 12/2018

23.05.2018 | Review Article

This is a call to oncologists for action

verfasst von: C. Micó, A. Berrocal, A. Blasco, C. Caballero, V. Iranzo, M. Lobo, C. Camps

Erschienen in: Clinical and Translational Oncology | Ausgabe 12/2018

Einloggen, um Zugang zu erhalten

Abstract

Cancer cases are growing in an exponential way, likewise the prices of new cancer drugs. Continuing in this way, in the near future, it will be impossible to provide optimum care for all cancer patients. Therefore, it is important to establish mechanisms that enable the National Health Systems to provide the best options of treatment, either through the elaboration of decision-binding frameworks or through other initiatives that guarantee the best quality care for all oncology patients to overcome, in the best possible way, this difficult illness. Here, we review current proposals that have been established by different cancer organizations worldwide, their similarities, their differences and whether they are helpful in a real clinical setting. Facing present reality and despite these organizations’ huge efforts, these proposals are not being implemented at all and it does not seem feasible that they will in the short run. In the same way, we support and argue why oncologists should have a crucial and a preponderant role to establish the best way of guaranteeing an equal access to the latest oncology care.
Literatur
1.
Zurück zum Zitat Ferlay J, Soerjomataram I, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.CrossRef Ferlay J, Soerjomataram I, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.CrossRef
4.
Zurück zum Zitat Sullivan R, Peppercorn J, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol. 2011;12(10):933–80.CrossRef Sullivan R, Peppercorn J, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol. 2011;12(10):933–80.CrossRef
5.
Zurück zum Zitat Stewart BW, Wild CP, editors. World cancer report. Lyon: International Agency for Research on Cancer; 2014. Stewart BW, Wild CP, editors. World cancer report. Lyon: International Agency for Research on Cancer; 2014.
6.
Zurück zum Zitat Fojo T, Mailankody S. Unintended consequences of expensive cancer therapeutics. The pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture. JAMA Otolaryngol Head Neck Surg. 2014;140:1225–36.CrossRef Fojo T, Mailankody S. Unintended consequences of expensive cancer therapeutics. The pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture. JAMA Otolaryngol Head Neck Surg. 2014;140:1225–36.CrossRef
8.
Zurück zum Zitat Kantarjian H, Steensma D. High cancer drug prices in the United States: reasons and proposed solutions. J Oncol Pract. 2014;10(4):e208–11.CrossRef Kantarjian H, Steensma D. High cancer drug prices in the United States: reasons and proposed solutions. J Oncol Pract. 2014;10(4):e208–11.CrossRef
9.
Zurück zum Zitat Walker J. High prices for drugs attacked at meeting. Wall Street J. 2015 (Health care). Walker J. High prices for drugs attacked at meeting. Wall Street J. 2015 (Health care).
11.
Zurück zum Zitat Mariotto AB, Yabroff KR, et al. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 2011;103:117–28.CrossRef Mariotto AB, Yabroff KR, et al. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 2011;103:117–28.CrossRef
13.
Zurück zum Zitat Mailankody S, Prasad V. Five years of cancer drug approvals: innovation, efficacy and costs. JAMA Oncol. 2015;1:539–40.CrossRef Mailankody S, Prasad V. Five years of cancer drug approvals: innovation, efficacy and costs. JAMA Oncol. 2015;1:539–40.CrossRef
14.
Zurück zum Zitat Howard DH, Bach PB, et al. Pricing in the market for anticancer drugs. J Econ Perspect. 2015;29:139–62.CrossRef Howard DH, Bach PB, et al. Pricing in the market for anticancer drugs. J Econ Perspect. 2015;29:139–62.CrossRef
15.
Zurück zum Zitat Weeks JC, Catalano PJ, et al. Patients’ expectations about effects of chemotherapy for advanced cancer. N Engl J Med. 2012;367:1616–25.CrossRef Weeks JC, Catalano PJ, et al. Patients’ expectations about effects of chemotherapy for advanced cancer. N Engl J Med. 2012;367:1616–25.CrossRef
16.
Zurück zum Zitat Prigerson HG, Bao Y, et al. Chemotherapy use, performance status, and quality of life at the end of life. JAMA Oncol. 2015;1:778–84.CrossRef Prigerson HG, Bao Y, et al. Chemotherapy use, performance status, and quality of life at the end of life. JAMA Oncol. 2015;1:778–84.CrossRef
17.
Zurück zum Zitat Whaley C, Schneider Chafen J, et al. Association between availability of health service prices and payments for these services. JAMA. 2014;312:1670–6.CrossRef Whaley C, Schneider Chafen J, et al. Association between availability of health service prices and payments for these services. JAMA. 2014;312:1670–6.CrossRef
18.
Zurück zum Zitat Wu SJ, Sylwestrzak G, et al. Price transparency for MRIs increased use of less costly providers and triggered provider competition. Health Aff. 2014;33:1391–8.CrossRef Wu SJ, Sylwestrzak G, et al. Price transparency for MRIs increased use of less costly providers and triggered provider competition. Health Aff. 2014;33:1391–8.CrossRef
19.
Zurück zum Zitat Altomare I, Irwin B, et al. Physician experience and attitudes toward addressing the cost of cancer care. J Oncol Pract. 2016;12:247–8.CrossRef Altomare I, Irwin B, et al. Physician experience and attitudes toward addressing the cost of cancer care. J Oncol Pract. 2016;12:247–8.CrossRef
20.
Zurück zum Zitat Schrag D, Hanger M. Medical oncologists’ views on communicating with patients about chemotherapy costs: a pilot survey. J Clin Oncol. 2007;25:233–7.CrossRef Schrag D, Hanger M. Medical oncologists’ views on communicating with patients about chemotherapy costs: a pilot survey. J Clin Oncol. 2007;25:233–7.CrossRef
22.
Zurück zum Zitat Cherny NI, Sullivan R, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO–MCBS). Ann Oncol. 2015;26:1547–73.CrossRef Cherny NI, Sullivan R, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO–MCBS). Ann Oncol. 2015;26:1547–73.CrossRef
23.
Zurück zum Zitat Cherny NI, Dafni U, et al. ESMO–magnitude of clinical benefit scale version 1.1. Ann Oncol. 2017;28:2340–66.CrossRef Cherny NI, Dafni U, et al. ESMO–magnitude of clinical benefit scale version 1.1. Ann Oncol. 2017;28:2340–66.CrossRef
24.
Zurück zum Zitat Schnipper LE, Davidson NE, et al. American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol. 2015;33:2563–77.CrossRef Schnipper LE, Davidson NE, et al. American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol. 2015;33:2563–77.CrossRef
25.
Zurück zum Zitat Schnipper LE, Davidson NE, et al. Updating the American Society of Clinical Oncology value framework: revisions and reflections in response to comments received. J Clin Oncol. 2016;34:2925–34.CrossRef Schnipper LE, Davidson NE, et al. Updating the American Society of Clinical Oncology value framework: revisions and reflections in response to comments received. J Clin Oncol. 2016;34:2925–34.CrossRef
26.
Zurück zum Zitat Becker DJ, Lin D, et al. Exploration of the ASCO and ESMO value frameworks for antineoplastic drugs. J Oncol Pract. 2017;13(7):e653–65 Becker DJ, Lin D, et al. Exploration of the ASCO and ESMO value frameworks for antineoplastic drugs. J Oncol Pract. 2017;13(7):e653–65
30.
Zurück zum Zitat Vivot A, Jacot J, et al. Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000–2015. Ann Oncol. 2017;28:1111–6.CrossRef Vivot A, Jacot J, et al. Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000–2015. Ann Oncol. 2017;28:1111–6.CrossRef
32.
Zurück zum Zitat Bentley TGK, Cohen JT. Validity and reliability of value assessment frameworks for new cancer drugs. Value Health. 2017;20:200–5.CrossRef Bentley TGK, Cohen JT. Validity and reliability of value assessment frameworks for new cancer drugs. Value Health. 2017;20:200–5.CrossRef
34.
Zurück zum Zitat World Health Organization. Health systems financing: the path to universal coverage. Geneva 2010. World Health Organization. Health systems financing: the path to universal coverage. Geneva 2010.
35.
Zurück zum Zitat Berwick DM, Hackbarth AD. Eliminating waste in US health care. JAMA. 2012;307:1513–6.CrossRef Berwick DM, Hackbarth AD. Eliminating waste in US health care. JAMA. 2012;307:1513–6.CrossRef
37.
Zurück zum Zitat Gauvreau CL, Fitzgerald NR, et al. The OncoSim model: development and use for better decision-making in Canadian cancer control. Curr Oncol. 2017;24(6):401–6.CrossRef Gauvreau CL, Fitzgerald NR, et al. The OncoSim model: development and use for better decision-making in Canadian cancer control. Curr Oncol. 2017;24(6):401–6.CrossRef
38.
Zurück zum Zitat Riva S, Pravettoni G. Value-based model: a new perspective in medical decision-making. Front Public Health. 2016;4:118.CrossRef Riva S, Pravettoni G. Value-based model: a new perspective in medical decision-making. Front Public Health. 2016;4:118.CrossRef
39.
Zurück zum Zitat Eaton KD, Jagels B, Martins RG. Value-based care in lung cancer. Oncologist. 2016;21:903–6.CrossRef Eaton KD, Jagels B, Martins RG. Value-based care in lung cancer. Oncologist. 2016;21:903–6.CrossRef
41.
Zurück zum Zitat Porter ME. What is value in health care? N Engl J Med. 2010;363:2477–81.CrossRef Porter ME. What is value in health care? N Engl J Med. 2010;363:2477–81.CrossRef
42.
Zurück zum Zitat Goulart BHL. Value: the next frontier in cancer care. Oncologist. 2016;21:651–3.CrossRef Goulart BHL. Value: the next frontier in cancer care. Oncologist. 2016;21:651–3.CrossRef
43.
Zurück zum Zitat Ken Lee KH, Matthew Austin J, Pronovost PJ. Developing a measure of value in healthcare. Value Health. 2016;19:323–5.CrossRef Ken Lee KH, Matthew Austin J, Pronovost PJ. Developing a measure of value in healthcare. Value Health. 2016;19:323–5.CrossRef
44.
Zurück zum Zitat Schrag D, Hanger M. Medical oncologists’ views on communicating with patients about chemotherapy costs: a pilot survey. J Clin Oncol. 2007;25:233–7.CrossRef Schrag D, Hanger M. Medical oncologists’ views on communicating with patients about chemotherapy costs: a pilot survey. J Clin Oncol. 2007;25:233–7.CrossRef
45.
Zurück zum Zitat Altomare I, Irwin B, et al. Physician experience and attitudes toward addressing the cost of cancer care. J Oncol Pract. 2014;10:e368–72.CrossRef Altomare I, Irwin B, et al. Physician experience and attitudes toward addressing the cost of cancer care. J Oncol Pract. 2014;10:e368–72.CrossRef
46.
Zurück zum Zitat Newcomer LN. Those who pay have a say: a view on oncology drug pricing and reimbursement. Oncologist. 2016;21(7):779–81CrossRef Newcomer LN. Those who pay have a say: a view on oncology drug pricing and reimbursement. Oncologist. 2016;21(7):779–81CrossRef
Metadaten
Titel
This is a call to oncologists for action
verfasst von
C. Micó
A. Berrocal
A. Blasco
C. Caballero
V. Iranzo
M. Lobo
C. Camps
Publikationsdatum
23.05.2018
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 12/2018
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-018-1887-3

Weitere Artikel der Ausgabe 12/2018

Clinical and Translational Oncology 12/2018 Zur Ausgabe

Correspondence

Letter to the Editor

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.